Efficacy of ezetimibe/simvastatin 10/20 and 10/40 mg compared with atorvastatin 20 mg in patients with type 2 diabetes mellitus

Diabetes, Obesity and Metabolism

Volumn 9, Issue 4, 2007, Pages 575-584

  Constance, Christine ^a   Westphal, S ^b   Chung, N ^c   Lund, M ^d   McCrary Sisk, C ^d   Johnson Levonas, A O ^d   Massaad, R ^e   Allen, C ^d  

^a MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^b OTTO VON GUERICKE UNIVERSITY   (Germany)

^c Yonsei University College of Medicine   (South Korea)

^d MERCK RESEARCH LABORATORIES   (United States)

^e Merck Sharp and Dohme   (Belgium)

Author keywords

Atorvastatin; Ezetimibe simvastatin; Low density lipoprotein cholesterol; Type 2 diabetes mellitus

Indexed keywords

APOLIPOPROTEIN B; ATORVASTATIN; CHOLESTEROL; EZETIMIBE PLUS SIMVASTATIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GALLBLADDER DISEASE; GASTROINTESTINAL SYMPTOM; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

EID: 34347399601     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2007.00725.x     Document Type: Article

References (40)

1. American Diabetes Association. Dyslipidemia management in adults with diabetes. Diabetes Care 2004; 27 (Suppl. 1): S68-S71.
2. Taskinen MR. Strategies for the management of diabetic dyslipidemia. Drugs 1999; 58 (Suppl. 1): 47-51.
3. Haffner SM. Management of dyslipidemia in adults with diabetes. Diabetes Care 2003; 26 (Suppl. 1): S83-S86.
4. Adult Treatment Panel III. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. JAMA 2001; 285: 2486-2497.
5. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 5693 people with diabetes: A randomised placebo-controlled trial. Lancet 2003; 361: 2005-2016.
6. Cannon CP, Braunwald E, McCabe CH et al. Comparison of intensive and moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495-1504.
7. Grundy SM, Cleeman JI, Merz NB et al. Implications of recent clinical trials for the national cholesterol education program. Adult treatment panel III guidelines. Circulation 2004; 110: 227-239.
8. Lewin A, Kipnes M, Meneghini L et al. Effects of simvastatin on the lipid profile and attainment of low-density lipoprotein cholesterol goals when added to thiazolidinedione therapy in patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, placebo-controlled trial. Clin Ther 2004; 26: 379-389.
9. Freed MI, Ratner R, Marcovina SM et al. Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus. Am J Cardiol 2002; 90: 947-952.
10. Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP): A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000; 160: 459-467.
11. Foley KA, Simpson RJ Jr, Crouse JR III, Weiss TW, Markson LE, Alexander CM. Effectiveness of statin titration on low-density lipoprotein cholesterol goal attainment in patients at high risk of atherogenic events. Am J Cardiol 2003; 92: 79-81.
12. Andrews TC, Ballantyne CM, Hsia JA, Kramer JH. Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins. Am J Med 2001; 111: 185-191.
13. Frolkis JP, Zyzanski SJ, Schwartz JM, Suhan PS. Physician noncompliance with the 1993 National Cholesterol Education Program (NCEP-ATPII) guidelines. Circulation 1998; 98: 851-855.
14. Van Heek M, France CF, Compton DS et al. In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461. J Pharmacol Exp Ther 1997; 283: 157-163.
15. Van Heek M, Farley C, Comptom DS et al. Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663. Br J Pharmacol 2000; 129: 1748-1754.
16. Knopp RH, Bays H, Manion CV et al. Effect of ezetimibe on serum concentrations of lipid-soluble vitamins. Atherosclerosis 2001; 2 (Suppl.): 90 (Abstract).
17. Kosoglou T, Meyer I, Veltri EP et al. Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin. Br J Clin Pharmacol 2002; 54: 309-319.
18. Gagne C, Bays HE, Weiss SR et al. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 2002; 90: 1084-1091.
19. Davidson MH, McGarry T, Bettis R et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 2002; 40: 2125-2134.
20. Ballantyne CM, Houri J, Notarbartolo A et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: A prospective, randomized, double-blind trial. Circulation 2003; 107: 2409-2415.
21. Goldberg AC, Sapre A, Liu J et al. Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: A randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 2004; 79: 620-629.
22. Gaudiani LM, Lewin A, Meneghini L et al. Efficacy and safety of ezetimibe co-administered with simvastatin in thiazolidinedione-treated type 2 diabetic patients. Diabetes Obes Metab 2005; 7: 88-97.
23. Myers GL, Cooper GR, Winn CL, Smith SJ. The Centers for Disease Control-National Heart, Lung, and Blood Institute Lipid Standardization Program: An approach to accurate and precise lipid measurements. Clin Lab Med 1989; 9: 105-135.
24. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
25. Manzato E, Zambon A, Lapolla A et al. Lipoprotein abnormalities in well-treated type II diabetic patients. Diabetes Care 1993; 16: 469-475.
26. International Diabetes Federation. Diabetes and Cardiovascular Disease: Time to Act. Brussels: International Diabetes Federation, 2001.
27. Hoerger TJ, Bala MV, Bray JW, Wilcosky TC, Larosa J. Treatment patterns and distribution of low-density lipoprotein cholesterol levels in treatment-eligible US adults. Am J Cardiol 1998; 82: 61-65.
28. Simons L, Tonlon M, Masana L et al. Effects of ezetimibe added to on-going statin therapy on the lipid profile of hypercholesterolemic patients with diabetes mellitus or metabolic syndrome. Curr Med Res Opin 2004; 20: 1437-1445.
29. Ballantyne CM, Blazing MA, King TR, Brady WE, Palmisano J. Efficacy and safety of ezetimibe coadministered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. Am J Cardiol 2004; 93: 1487-1494.
30. Haffner SM, Alexander CM, Cook TJ et al. for the Scandinavian Simvastatin Survival Study Group. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels. Arch Intern Med 1999; 159: 2661-2667.
31. Colhoun HM, Betteridge DJ, Durrington PN et al. on behalf of the CARDS Investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomized placebo-controlled trial. Lancet 2004; 364: 685-696.
32. Sever PS, Dahlöf B, Poulter NR et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): A multicentre randomized controlled trial. Lancet 2003; 361: 1149-1158.
33. Frost PH, Havel RJ. Rationale for use of non-high-density lipoprotein cholesterol rather than low-density lipoprotein cholesterol as a tool for lipoprotein cholesterol screening and assessment of risk and therapy. Am J Cardiol 1998; 81: 26B-31B.
34. Lamarche B, Moorjani S, Lupien PJ et al. Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Quebec cardiovascular study. Circulation 1996; 94: 273-278.
35. Jones PH, Davidson MH, Stein EA et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 2003; 92: 152-160.
36. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836-843.
37. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347: 1557-1565.
38. Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB. Production of C-reactive protein and risk of coronary events in stable and unstable angina European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 1997; 349: 426-462.
39. Pietila KO, Harmoinen AP, Jokinitty J, Pasternack AI. Serum C-reactive protein concentration in acute myocardial infarction and its relationship to mortality during 24 months of follow-up in patients under thrombolytic treatment. Eur Heart J 1996; 17: 1345-1349.
40. Sager P, Melani L, Lipka L et al. Effect of coadministration of ezetimibe and simvastatin on high-sensitivity C-reactive protein. Am J Cardiol 92: 1414-1418.